An outdated notion of antibody specificity is one of the major detrimental assumptions of the structure-based reverse vaccinology paradigm, which prevented it from helping to develop an effective HIV-1 vaccine

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  van Regenmortel, Marc H V ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Antibody polyspecificity; HIV 1 vaccines; Immunological explanations; Paradigm; Structure based reverse vaccinology

Indexed keywords

ANTIGEN; B LYMPHOCYTE RECEPTOR; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROTEIN;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGENICITY; BINDING AFFINITY; CLINICAL TRIAL (TOPIC); CRYSTALLOGRAPHY; GENOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; STRUCTURE BASED REVERSE VACCINOLOGY; VACCINATION;

EID: 84919443137     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00593     Document Type: Review

References (108)

1. Kuhn TS. The Structure of Scientific Revolutions. Chicago: University of Chicago Press (1962).
2. Horgan J. The End of Science. New York, NY: Broadway Books (1996). p. 41-7.
3. Popper K. The Logic of Scientific Discovery. London: Hutchinson (1959).
4. Horgan J. The End of Science. New York, NY: Broadway Books (2006). p. 32-41.
5. Bird A. Thomas Kuhn. Fall 2013 ed. In: Zalta EN, editor. The Stanford Encyclopedia of Philosophy. (2013). Available from: http://plato.stanford.edu/entries/thomas-kuhn/
6. Esparza J. The global HIV vaccine enterprise. Int Microbiol (2005) 8:93-101.
7. Esparza J. What has 30 years of HIV research taught us? Vaccines (2013) 1:513-26. doi: 10.3390/vaccines1040513
8. Van Regenmortel MHV, Andrieu J-M, Dimitrov DS, Ensoli B, Hioe CE, Moog C, et al. Paradigm changes and the future of HIV vaccine research: a summary of a workshop held in Baltimore on 20 November 2013. J AIDS Clin Res (2014) 5:281. doi:10.4172/2155-6113.1000281
9. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol (2002) 2:706-13. doi:10.1038/nri891
10. Van Regenmortel MHV. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch Virol (2012) 157:1-20. doi:10.1007/s00705-011-1145-2
11. Van Regenmortel MHV. Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol (2012) 3:194. doi:10.3389/fimmu.2012.00194
12. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine (2001) 19:2688-91. doi:10.1016/S0264-410X(00)00554-5
13. Rappuoli R, Bagnoli F. Vaccine Design. Norfolk: Carster Academic Press (2011).
14. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 22:358-66. doi:10.1016/j.coi.2010.02.012
15. Van Regenmortel MHV. Synthetic peptide vaccines and the search for neutralization of B cell epitopes. Open Vaccin J (2009) 2:33-44. doi:10.2174/1875035401002010033
16. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe (2012) 12:396-407. doi:10.1016/j.chom.2012.09.008
17. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Ann Rev Immunol (2013) 31:705-42. doi:10.1146/annurev-immunol-032712-095916
18. Van Regenmortel MHV. Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine (2011) 29:7875. doi:10.1016/j.vaccine.2011.08.063
19. Kong L, Sattentau QJ. Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clin Res (2012) 8:3. doi:10.4172/2155-6113.S8-003
20. Sundberg EJ, Mariuzza RA. Molecular recognition in antibody-antigen complexes. Adv Protein Chem (2002) 61:119-60. doi:10.1016/S0065-3233(02)61004-6
21. Schildbach JF, Near RI, Bruccoleri RE, Haber E, Jeffrey PD, Novotny J, et al. Modulation of antibody affinity by a non-contact residue. Protein Sci (1993) 2:206-14. doi:10.1002/pro.5560020209
22. Chatellier J, Van Regenmortel MHV, Vernet T, Altschuh D. Functional mapping of conserved residues located at the VL and VH domain interface of a Fab. J Mol Biol (1996) 264:1-6. doi:10.1006/jmbi.1996.0618
23. Greenspan NS, DiCera E. Defining epitopes: it's not as easy as it seems. Nat Biotechnol (1999) 17:936-7. doi:10.1038/13590
24. Moudgil KD, Sercarz EE, Grewal IS. Modulation of the immunogenicity of antigenic determinants by their flanking residues. Immunol Today (1998) 19:217-20. doi:10.1016/S0167-5699(97)01233-4
25. Cunningham BC, Wells JA. Comparison of a structural and a functional epitope. J Mol Biol (1993) 234:554-63. doi:10.1006/jmbi.1993.1611
26. Wilson IA, Stanfield RL. Antibody-antigen interactions: new structures and new conformational changes. Curr Opin Struct Biol (1994) 4:857-67. doi:10.1016/0959-440X(94)90267-4
27. Bosshard HR. Molecular recognition by induced fit: how fit is the concept? News Physiol Sci (2001) 16:171-3.
28. Joyce JG, Hurni WM, Bogusky MJ, Garsky VM, Liang X, Citron MP, et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem (2002) 277:45811-20. doi:10.1074/jbc.M205862200
29. Ho J, Uger RA, Zwick MB, Luscher MA, Barber BH, MacDonald KS. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine (2005) 23:1559-73. doi:10.1016/j.vaccine.2004.09.037
30. Burton DR. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci U S A (2010) 107:17859-60. doi:10.1073/pnas.1012923107
31. Pejchal R, Wilson IA. Structure-based vaccine design in HIV: blind men and the elephant? Curr Pharm Des (2010) 16:3744-53. doi:10.2174/138161210794079173
32. Van Regenmortel MHV. Limitations to the structure-based design of HIV-1vaccine immunogens. J Mol Recognit (2011) 24:741-53. doi:10.1002/jmr.1116
33. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 390:404-9. doi:10.1016/j.bbrc.2009.09.029
34. Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. MAbs (2010) 2:347-56. doi:10.4161/mabs.2.3.11779
35. Zhu Z, Qin HR, Chen W, Zhao Q, Shen X, Schutte R, et al. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol (2011) 85:11401-8. doi:10.1128/JVI.05312-11
36. Chen W, Streaker ED, Russ DE, Feng Y, Prabakaran P, Dimitrov D. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun (2012) 417:1164-9. doi:10.1016/j.bbrc.2011.12.089
37. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 153:126-38. doi:10.1016/j.cell.2013.03.018
38. Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 340:711-6. doi:10.1126/science.1234150
39. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis (2008) 197:846-53. doi:10.1086/528801
40. Burton DR, Stanfield RL, Wilson IA. Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A (2005) 102:14943-8. doi:10.1073/pnas.0505126102
41. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 342:592-8. doi:10.1126/science.1243283
42. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 496:469-76. doi:10.1038/nature12053
43. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 85:4828-40. doi:10.1128/JVI.00198-11
44. Euler Z, van den Kerkhof TL, van Gils MJ, Burger JA, Edo-Matas D, Phung P, et al. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol (2012) 86:2045-55. doi:10.1128/JVI.06091-11
45. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 333:1593-602. doi:10.1126/science.1207532
46. Mouquet H, Nussenzweig MC. HIV: roadmaps to a vaccine. Nature (2013) 496:441-2. doi:10.1038/nature12091
47. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 30:423-33. doi:10.1038/nbt.2197
48. Fauci AS, Marston HD. Ending AIDS - is an HIV vaccine necessary? N Engl J Med (2014) 370:495-8. doi:10.1056/NEJMp1313771
49. Prabakaran P, Chen W, Dimitrov DS. The antibody germline/maturation hypothesis, elicitation of broadly neutralizing antibodies against HIV-1 and cord blood IgM repertoires. Front Immunol (2014) 5:398. doi:10.3389/fimmu.2014.00398
50. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 458:636-40. doi:10.1038/nature07930
51. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 15:866-70. doi:10.1038/nm.1949
52. Sattentau QJ, McMichael AJ. New templates for HIV-1 antibody-based vaccine design. F1000 Biol Rep (2010) 2:60. doi:10.3410/B2-60
53. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol (2010) 28:413-44. doi:10.1146/annurev-immunol-030409-101256
54. Burton DR, Weiss RA. AIDS/HIV. A boost for HIV vaccine design. Science (2010) 329:770-3. doi:10.1126/science.1194693
55. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol (1999) 73:4009-18.
56. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, Smith BA, Baba TW, Liska V, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol (2001) 75:7470-80. doi:10.1128/JVI.75.16.7470-7480.2001
57. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, Lapedes A, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2010) 84:1631-6. doi:10.1128/JVI.01482-09
58. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol (1994) 68:4001-8.
59. Mascola JR. HIV/AIDS: allied responses. Nature (2007) 449:29-30. doi:10.1038/449029a
60. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, Burton DR, et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 75:12198-208. doi:10.1128/JVI.75.24.12198-12208.2001
61. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 266:1024-7. doi:10.1126/science.7973652
62. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 326:285-9. doi:10.1126/science.1178746
63. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 329:856-61. doi:10.1126/science.1187659
64. Van Regenmortel MHV. Reductionism and the search for structure-function relationships in antibody molecules. J Mol Recognit (2002) 15:240-7. doi:10.1002/jmr.584
65. Van Regenmortel MHV. Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological complexity and overcome the limitations of reductionism. EMBO J (2004) 5:1016-20. doi:10.1038/sj.embor.7400284
66. Van Regenmortel MHV, Hull D. Promises and Limits of Reductionism in the Biomedical Sciences. Chichester: Wiley (2002).
67. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 72:54-84. doi:10.1128/MMBR.00020-07
68. Sperling R, Francus T, Siskind GW. Degeneracy of antibody specificity. J Immunol (1983) 131:882-5.
69. Berek C, Milstein C. Mutation drift and repertoire shift in the maturation of the immune response. Immunol Rev (1987) 96:23-41. doi:10.1111/j.1600-065X.1987.tb00507.x
70. Chen ZJ, Wheeler CJ, Shi W, Wu AJ, Yarboro CH, Gallagher M, et al. Polyreactive antigen-binding B cells are the predominant cell type in the newborn B cell repertoire. Eur J Immunol (1998) 28:989-94. doi:10.1002/(SICI)1521-4141(199803)28:03<989::AID-IMMU989>3.0.CO;2-1
71. Parnes O. From interception to incorporation: degeneracy and promiscuous recognition as precursors of a paradigm shift in immunology. Mol Immunol (2004) 40:985-91. doi:10.1016/j.molimm.2003.11.021
72. Cohen IR, Hershberg U, Solomon S. Antigen-receptor degeneracy and immunological paradigms. Mol Immunol (2004) 40:993-6. doi:10.1016/j.molimm.2003.11.020
73. Notkins AL. Polyreactivity of antibody molecules. Trends Immunol (2004) 25:174-9. doi:10.1016/j.it.2004.02.004
74. Eisen HN, Chakraborty AK. Evolving concepts of specificity in immune reactions. Proc Natl Acad Sci U S A (2010) 107:22373-80. doi:10.1073/pnas.1012051108
75. Wucherpfennig KW, Allen PM, Celada F, Cohen IR, De Boer R, Garcia KC, et al. Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 19:216-24. doi:10.1016/j.smim.2007.02.012
76. Van Regenmortel MHV. Specificity, polyspecificity and heterospecificity of antibody-antigen recognition. J Mol Recognit (2014) 27:627-39. doi:10.1002/jmr.2394
77. Manivel V, Bayiroglu F, Siddiqui Z, Salunke DM, Rao KV. The primary antibody repertoire represents a linked network of degenerate antigen specificities. J Immunol (2002) 169:888-97. doi:10.4049/jimmunol.169.2.888
78. Yin J, Beuscher AE IV, Andryski SE, Stevens RC, Schultz PG. Structural plasticity and the evolution of antibody affinity and specificity. J Mol Biol (2003) 330:651-6. doi:10.1016/S0022-2836(03)00631-4
79. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: a hypothesis. Hum Antibodies (2005) 14:59-67.
80. Zhou ZH, Zhang Y, Hu YF, Wahl LM, Cisar JO, Notkins AL. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe (2007) 15:51-61. doi:10.1016/j.chom.2007.01.002
81. Mouquet H, Nussenzweig MC. Polyreactive antibodies in adaptive immune responses to viruses. Cell Mol Life Sci (2012) 69:1435-45. doi:10.1007/s00018-011-0872-6
82. Mariuzza RA. Multiple paths to multispecificity. Immunity (2006) 24:359-61. doi:10.1016/j.immuni.2006.03.009
83. Berzofsky JA. Intrinsic and extrinsic factors in protein antigenic structure. Science (1985) 229:932-40. doi:10.1126/science.2410982
84. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature (2012) 492:118-22. doi:10.1038/nature11604
85. Doria-Rose NA. HIV neutralizing antibodies: clinical correlates and implications for vaccines. J Infect Dis (2010) 201:981-3. doi:10.1086/651143
86. Euler Z, van Gils MJ, Bunnik EM, Phung P, Schweighardt B, Wrin T, et al. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 201:1045-53. doi:10.1086/651144
87. van Gils MJ, Bunnik EM, Burger JA, Jacob Y, Schweighardt B, Wrin T, et al. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term non progressors. J Virol (2010) 84:3576-85. doi:10.1128/JVI.02622-09
88. Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, et al. Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic. J Virol (2011) 85:7236-45. doi:10.1128/JVI.00196-11
89. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 6:143-55. doi:10.1038/nrmicro1819
90. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell (2006) 124:677-81. doi:10.1016/j.cell.2006.02.005
91. Nabel GJ, Kwong PD, Mascola JR. Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci (2011) 366:2759-65. doi:10.1098/rstb.2011.0096
92. Van Regenmortel MHV. Molecular design versus empirical discovery in peptide-based vaccines. Coming to terms with fuzzy recognition sites and ill-defined structure-function relationships in immunology. Vaccine (1999) 18:216-21. doi:10.1016/S0264-410X(99)00192-9
93. Kuntz ID. Structure-based strategies for drug design and discovery. Science (1992) 257:1078-82. doi:10.1126/science.257.5073.1078
94. Van Regenmortel MHV. The rational design of biological complexity: a deceptive metaphor. Proteomics (2007) 7:965-75. doi:10.1002/pmic.200600407
95. Schiffner T, Sattentau QJ, Dorrell L. Development of prophylactic vaccines against HIV-1. Retrovirology (2013) 10:72. doi:10.1186/1742-4690-10-72
96. Salmon WC. Causality and Explanation. Oxford: Oxford University Press (1998).
97. Lipton P. What good is an explanation? In: Cornwell J, editor. Explanations. Styles of Explanation in Science. Oxford: Oxford University Press (2004). p. 1-21.
98. Dupré J. The Disorder of Things. Metaphysical Foundations of the Disunity of Science. Cambridge, MA: Harvard University Press (1993).
99. Gannon F. Too complex to comprehend? EMBO Rep (2007) 8:705. doi:10.1038/sj.embor.7401041
100. Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F, Gao H, et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science (2011) 334:1289-93. doi:10.1126/science.1213782
101. Gunawardena J. Models in biology: 'accurate descriptions of our pathetic thinking'. BMC Biol (2014) 12:29. doi:10.1186/1741-7007-12-29
102. Ylikoski P. The illusion of depth of understanding in science. In: De Regt HW, Leonelli S, Eigner K, editors. Scientific Understanding. Pittsburgh: University of Pittsburgh Press (2009). p. 100-19.
103. Van Fraassen BC. Experience. The Empirical Stance. New Haven: Yale University Press (2002). p. 111-52.
104. Hacking Ian. Representing and Intervening. Introductory Topics in the Philosophy of Natural Science. Cambridge, UK: Cambridge University Press (1983). 287 p.
105. Leonelli S. Understanding in biology: the impure nature of biological knowledge. In: De Regt HW, Leonelli S, Eigner K, editors. Scientific Understanding. Pittsburgh: University of Pittsburgh Press (2009). p. 189-209.
106. Kelley L, Scott M. The evolution of biology. EMBO Rep (2008) 9:1163-7. doi:10.1038/embor.2008.212
107. Sok D, Doores KJ, Briney B, Le KM, Saye-Francisco KL, Ramos A, et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med (2014) 6:236ra63. doi:10.1126/scitranslmed.3008104
108. Alberts B, Kirschner MW, Tilghman S, Varmus H. Rescuing US biomedical research from its systemic flaws. Proc Natl Acad Sci U S A (2014) 111:5773-7. doi:10.1073/pnas.1404402111